• Skip to main content
  • Skip to footer
cnb1383_liver-model-drug-safety_webinar_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Organ-on-a-Chip Resources

Resource type

Area of interest

Blogs

Resource image

Why the FDA animal testing phase-out for monoclonal antibodies?

In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal antibodies, followed by other drugs – signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing.

Blogs

Resource image

Microphysiological systems for mAbs development: how do they address animal limitations?

Part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs).

Articles

Resource image

How OOC can improve in vitro to in vivo translatability of preclinical data

Articles

Resource image

Organ-on-a-chip: a modernized toolbox for drug discovery challenges

Transforming drug discovery with a modernised toolbox. OOC is transforming accuracy, reducing failures, and accelerating new therapies.

Videos and animations

Resource image

PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.

Videos and animations

Resource image

PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights

Confidently predict DILI with PhysioMimix DILI assay kit: Human 24-accurate, human-relevant mechanistic hepatotoxicity insights to enhance drug safety in development

Webinars

Resource image

Advancing oligonucleotide therapies with liver-on-a-chip models

Webinar Series 8 Episode 1

Discover how human-relevant models improve the understanding of drug delivery, efficacy, and safety of oligonucleotide therapies.

Application notes

Resource image

A liver microphysiological system to study the delivery and efficacy of oligonucleotide-based therapeutics

We introduce the PhysioMimix Liver MPS to study the delivery of oligonucleotides into the liver and their uptake by PHHs. The Liver MPS produces functional and stable PHH microtissues, enabling the study of gene knockdown and dosing strategies over 14 days.

Articles

Resource image

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

Scientific publications

Resource image

Multimodal imaging of a liver-on-a-chip model using labelled and label-free optical microscopy techniques

This recent multimodal imaging publication by Majer et al. (2024) from GSK explores the groundbreaking potential of 3D imaging of Liver-on-a-chip tissue to evaluate one of the biggest challenges in therapeutic ASOs: delivering oligonucleotides in sufficient concentration to the target tissue and cells of interest.

Videos and animations

Resource image

Validating a human dual-organ MPS for better drug (ADME) studies

In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology can be used to evaluate the body’s effect on drugs.

Blogs

Resource image

The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches

When developing oligonucleotide therapeutics, human-centric approaches are crucial for overcoming ADMET challenges and unlocking their full potential.

Find out through case studies how and why Organ-on-a-chip offers a path forward for the development of oligonucleotides targeting liver diseases by providing clearer insights into human-specific responses where in vivo models are less/unsuited.

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
  • Why the FDA animal testing phase-out for monoclonal antibodies? May 1, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research April 29, 2025
Cyber Essentials Logo